دورية أكاديمية
Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson's Disease.
| العنوان: | Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson's Disease. |
|---|---|
| المؤلفون: | Soares ÉN; Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador 40110-902, BA, Brazil., Costa ACDS; Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador 40110-902, BA, Brazil., Ferrolho GJ; Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador 40110-902, BA, Brazil.; Laboratory of Neurosciences, Institute of Health Sciences, Federal University of Bahia, Salvador 40110-902, BA, Brazil., Ureshino RP; Department of Biological Sciences, Universidade Federal de São Paulo, Diadema 09961-400, SP, Brazil.; Laboratory of Molecular and Translational Endocrinology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo 04039-032, SP, Brazil., Getachew B; Department of Pharmacology, College of Medicine, Howard University, 520 W Street NW, Washington, DC 20059, USA., Costa SL; Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador 40110-902, BA, Brazil., da Silva VDA; Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador 40110-902, BA, Brazil.; Laboratory of Neurosciences, Institute of Health Sciences, Federal University of Bahia, Salvador 40110-902, BA, Brazil., Tizabi Y; Department of Pharmacology, College of Medicine, Howard University, 520 W Street NW, Washington, DC 20059, USA. |
| المصدر: | Cells [Cells] 2024 Mar 07; Vol. 13 (6). Date of Electronic Publication: 2024 Mar 07. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مواضيع طبية MeSH: | Parkinson Disease*/metabolism , Receptors, Nicotinic*/metabolism , Neurodegenerative Diseases*/metabolism, Humans ; Nicotine/metabolism ; Dopamine/metabolism ; Astrocytes/metabolism |
| مستخلص: | Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by resting tremor, bradykinesia, rigidity, and postural instability that also includes non-motor symptoms such as mood dysregulation. Dopamine (DA) is the primary neurotransmitter involved in this disease, but cholinergic imbalance has also been implicated. Current intervention in PD is focused on replenishing central DA, which provides remarkable temporary symptomatic relief but does not address neuronal loss and the progression of the disease. It has been well established that neuronal nicotinic cholinergic receptors (nAChRs) can regulate DA release and that nicotine itself may have neuroprotective effects. Recent studies identified nAChRs in nonneuronal cell types, including glial cells, where they may regulate inflammatory responses. Given the crucial role of neuroinflammation in dopaminergic degeneration and the involvement of microglia and astrocytes in this response, glial nAChRs may provide a novel therapeutic target in the prevention and/or treatment of PD. In this review, following a brief discussion of PD, we focus on the role of glial cells and, specifically, their nAChRs in PD pathology and/or treatment. |
| References: | Curr Neuropharmacol. 2018;16(4):338-349. (PMID: 28901280) Respir Physiol. 2001 Dec;129(1-2):71-81. (PMID: 11738647) Iran J Allergy Asthma Immunol. 2018 Aug 12;17(4):372-378. (PMID: 30537800) Stem Cell Res Ther. 2022 Mar 21;13(1):117. (PMID: 35314006) J Clin Med. 2023 Jun 30;12(13):. (PMID: 37445461) Brain. 2020 Oct 1;143(10):3077-3088. (PMID: 32830221) Front Neurosci. 2020 Aug 06;14:844. (PMID: 32848588) Clin Pharmacol Transl Med. 2017;1(1):14-19. (PMID: 29863173) Brain Sci. 2023 Jun 05;13(6):. (PMID: 37371389) PLoS One. 2014 May 15;9(5):e97096. (PMID: 24830807) Neurotoxicology. 2016 Jul;55:10-12. (PMID: 27168424) Cogn Neurodyn. 2023 May 19;:1-6. (PMID: 37362764) Front Cell Neurosci. 2022 Dec 06;16:956185. (PMID: 36561497) Nat Commun. 2022 Aug 25;13(1):5014. (PMID: 36008394) Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1454-1463. (PMID: 28167231) Int Rev Neurobiol. 2015;124:3-19. (PMID: 26472524) Pharmacol Res. 2023 Aug;194:106860. (PMID: 37482325) Cell Death Dis. 2023 Mar 1;14(3):176. (PMID: 36859484) Curr Opin Neurol. 2023 Aug 1;36(4):292-301. (PMID: 37366140) Neurobiol Dis. 2018 Sep;117:170-180. (PMID: 29859873) Semin Neurol. 2017 Apr;37(2):118-126. (PMID: 28511252) Neuropharmacology. 2021 Nov 1;199:108758. (PMID: 34433089) J Neural Transm (Vienna). 2018 Aug;125(8):1251-1262. (PMID: 29492663) Int J Mol Sci. 2023 Mar 30;24(7):. (PMID: 37047495) Pharmacol Biochem Behav. 2005 Aug;81(4):879-86. (PMID: 16045972) Neural Regen Res. 2022 Jul;17(7):1404-1411. (PMID: 34916410) Clin Geriatr Med. 2020 Feb;36(1):1-12. (PMID: 31733690) Nat Rev Neurol. 2023 Jul;19(7):395-409. (PMID: 37308616) Neurotox Res. 2023 Dec 14;42(1):3. (PMID: 38095760) Neuron. 2021 Jul 21;109(14):2292-2307.e5. (PMID: 34102111) Glia. 2023 Feb;71(2):155-167. (PMID: 35971989) J Neuroinflammation. 2023 Oct 4;20(1):223. (PMID: 37794488) PLoS One. 2013;8(2):e55886. (PMID: 23437071) Pharmacol Ther. 2021 Mar;219:107693. (PMID: 32987056) Brain Sci. 2023 Apr 07;13(4):. (PMID: 37190599) Cell Commun Signal. 2024 Jan 12;22(1):31. (PMID: 38216911) Antioxidants (Basel). 2023 Mar 09;12(3):. (PMID: 36978921) Nat Rev Neurol. 2023 May;19(5):278-288. (PMID: 36977843) Front Neurol. 2020 May 08;11:395. (PMID: 32457695) Int J Mol Sci. 2023 Dec 26;25(1):. (PMID: 38203531) Eur J Neurosci. 2023 Aug 4;:. (PMID: 37539749) Pharmacol Res. 2023 Nov;197:106975. (PMID: 38032294) Neuropharmacology. 2020 Jun 15;170:108053. (PMID: 32188568) Neurosci Bull. 2011 Dec;27(6):413-21. (PMID: 22108818) Glia. 2023 Jun;71(6):1481-1501. (PMID: 36802096) Int J Mol Sci. 2023 Oct 29;24(21):. (PMID: 37958716) Front Cell Neurosci. 2021 Aug 31;15:718324. (PMID: 34531726) J Neurosci Res. 2018 Jan;96(1):160-171. (PMID: 28573674) Semin Cell Dev Biol. 2019 Nov;95:142-150. (PMID: 30951895) ASN Neuro. 2023 Jan-Dec;15:17590914231155976. (PMID: 37017068) Cell. 2010 Mar 19;140(6):918-34. (PMID: 20303880) Ageing Res Rev. 2023 Feb;84:101812. (PMID: 36455790) Pharmacol Res. 2023 Apr;190:106715. (PMID: 36868367) J Neurosci. 2006 Oct 25;26(43):10984-91. (PMID: 17065440) Front Cell Dev Biol. 2023 Jul 26;11:1221890. (PMID: 37564376) Psychopharmacology (Berl). 2021 Feb;238(2):589-597. (PMID: 33216167) Mini Rev Med Chem. 2020;20(9):754-767. (PMID: 31686637) Front Neurosci. 2022 Apr 12;16:845646. (PMID: 35495050) Mini Rev Med Chem. 2023;23(20):1959-1974. (PMID: 37198991) Neurosci Lett. 2020 May 14;727:134916. (PMID: 32194135) Int J Mol Sci. 2023 Sep 26;24(19):. (PMID: 37834017) Front Behav Neurosci. 2017 Jan 05;10:244. (PMID: 28105008) Life (Basel). 2021 Nov 16;11(11):. (PMID: 34833115) Cell Metab. 2021 Aug 3;33(8):1546-1564. (PMID: 34348099) Autophagy. 2014 Apr;10(4):618-30. (PMID: 24434817) Biomedicines. 2022 Dec 24;11(1):. (PMID: 36672549) Prog Neurobiol. 2024 Jan;232:102548. (PMID: 38040324) Neurotox Res. 2020 Oct;38(3):596-602. (PMID: 32572814) Biomedicines. 2023 Oct 14;11(10):. (PMID: 37893165) Aust J Gen Pract. 2021 Nov;50(11):812-817. (PMID: 34713279) Mol Med. 2003 May-Aug;9(5-8):125-34. (PMID: 14571320) Curr Pharm Des. 2008;14(30):3247-66. (PMID: 19075704) Biomolecules. 2023 Oct 19;13(10):. (PMID: 37892231) Biomolecules. 2022 Jan 23;12(2):. (PMID: 35204690) Cells. 2023 Mar 25;12(7):. (PMID: 37048085) Biol Psychiatry. 2002 Jan 15;51(2):164-71. (PMID: 11822995) Neurotox Res. 2012 Aug;22(2):177-80. (PMID: 22528249) J Neurol Sci. 2022 Feb 15;433:120017. (PMID: 34629180) Cell Mol Neurobiol. 2022 Jul;42(5):1283-1300. (PMID: 33387119) Neuropharmacology. 2020 May 15;168:108021. (PMID: 32146229) J Neurosci Res. 2012 Feb;90(2):388-98. (PMID: 21971760) Front Endocrinol (Lausanne). 2022 Jul 27;13:953995. (PMID: 35966104) Neurotox Res. 2021 Apr;39(2):182-190. (PMID: 33555546) Neurotoxicology. 2017 Mar;59:49-55. (PMID: 28082123) Cold Spring Harb Perspect Biol. 2024 Jan 2;16(1):. (PMID: 38167424) Acta Diabetol. 2023 Aug;60(8):1007-1017. (PMID: 37058160) Arq Neuropsiquiatr. 1995 Mar;53(1):1-10. (PMID: 7575192) J Exp Med. 2005 Oct 17;202(8):1017-21. (PMID: 16230472) CNS Neurol Disord Drug Targets. 2020;19(10):725-740. (PMID: 32881676) Pharmacol Res. 2018 Feb;128:101-109. (PMID: 29051105) Mov Disord. 2023 Feb;38(2):244-255. (PMID: 36416213) Front Mol Neurosci. 2023 Jun 08;16:1169320. (PMID: 37363320) J Neurochem. 2024 Jan;168(1):3-25. (PMID: 38055776) Pharmacol Res. 2023 May;191:106759. (PMID: 37023990) Int J Mol Sci. 2020 Jul 12;21(14):. (PMID: 32664647) J Neurosci Res. 2005 Jan 1-15;79(1-2):157-65. (PMID: 15573410) Ultrastruct Pathol. 2022 Jan 2;46(1):37-53. (PMID: 35001795) Front Neurosci. 2023 Aug 31;17:1239009. (PMID: 37719154) J Neurosci. 2011 Nov 9;31(45):16064-9. (PMID: 22072657) Physiology (Bethesda). 2024 Jan 1;39(1):0. (PMID: 37962895) Neurotox Res. 2021 Aug;39(4):1381-1390. (PMID: 34003454) Acta Neurol Scand. 2016 Nov;134(5):314-326. (PMID: 26869347) Int J Mol Sci. 2023 Jul 05;24(13):. (PMID: 37446304) Glia. 2024 Feb;72(2):245-273. (PMID: 37772368) Brain Sci. 2022 Jan 28;12(2):. (PMID: 35203939) Transl Neurodegener. 2014 May 09;3:10. (PMID: 24826210) Int J Mol Sci. 2023 Jan 23;24(3):. (PMID: 36768596) Biomedicines. 2023 Mar 16;11(3):. (PMID: 36979901) Int J Mol Sci. 2023 Dec 23;25(1):. (PMID: 38203424) Front Neurosci. 2022 Feb 16;16:824888. (PMID: 35250459) Neurobiol Dis. 2023 Nov;188:106337. (PMID: 37918758) Nat Commun. 2020 Aug 21;11(1):4183. (PMID: 32826893) J Alzheimers Dis. 2019;69(4):905-919. (PMID: 31104014) Front Neurol. 2023 Mar 07;14:1103416. (PMID: 36959826) Mol Aspects Med. 2021 Dec;82:100972. (PMID: 34130867) Front Immunol. 2022 Feb 18;13:826889. (PMID: 35251010) Science. 2020 Feb 7;367(6478):. (PMID: 32029601) J Integr Neurosci. 2023 Oct 23;22(6):148. (PMID: 38176933) Nat Rev Neurosci. 2018 Apr;19(4):235-249. (PMID: 29515192) Adv Neurobiol. 2021;26:3-19. (PMID: 34888828) Cells. 2023 Feb 15;12(4):. (PMID: 36831289) Pharmacol Res. 2023 May;191:106758. (PMID: 37028776) Neurotox Res. 2005 Nov;8(3-4):289-93. (PMID: 16371323) Glia. 2018 Jun;66(6):1176-1184. (PMID: 29411421) J Neuroimmune Pharmacol. 2021 Jun;16(2):390-402. (PMID: 32564332) Neurochem Int. 2019 Mar;124:19-24. (PMID: 30557592) Front Neurosci. 2023 Dec 22;17:1308345. (PMID: 38188026) Immunity. 2022 Dec 13;55(12):2236-2254. (PMID: 36351425) Molecules. 2021 Oct 11;26(20):. (PMID: 34684720) Life (Basel). 2021 Mar 09;11(3):. (PMID: 33803153) Curr Pharm Des. 2016;22(10):1305-11. (PMID: 26972289) Neuron. 2023 Dec 20;111(24):4006-4023.e10. (PMID: 38128479) Curr Pharm Des. 2014;20(7):1082-96. (PMID: 23782147) Neurosci Biobehav Rev. 2018 Jan;84:289-298. (PMID: 28859996) Front Hum Neurosci. 2009 Nov 09;3:31. (PMID: 19915731) Nat Aging. 2023 Mar;3(3):246-247. (PMID: 36993868) Neurobiol Dis. 2023 May;180:106076. (PMID: 36921779) Curr Opin Neurobiol. 2023 Dec;83:102797. (PMID: 37832393) Curr Opin Immunol. 2022 Jun;76:102177. (PMID: 35462279) Nat Med. 2022 Oct;28(10):2045-2055. (PMID: 36216941) J Pharmacol Sci. 2020 Nov;144(3):102-118. (PMID: 32921391) J Neuroimmunol. 2019 Jul 15;332:16-30. (PMID: 30928868) Glia. 2009 Aug 1;57(10):1104-14. (PMID: 19170184) Mol Neurobiol. 2023 Oct 18;:. (PMID: 37851313) Glia. 2017 May;65(5):687-698. (PMID: 28101995) Front Cell Neurosci. 2021 Feb 23;15:645240. (PMID: 33708075) Front Aging Neurosci. 2021 May 05;13:640674. (PMID: 34025390) Glia. 2014 Aug;62(8):1195-210. (PMID: 24753030) Neurol India. 2019 Jul-Aug;67(4):968-978. (PMID: 31512617) Front Med. 2024 Jan 13;:. (PMID: 38216854) Glia. 2013 Mar;61(3):349-60. (PMID: 23108585) Ann Transl Med. 2021 Mar;9(6):509. (PMID: 33850906) Neurochem Res. 2015 Dec;40(12):2570-82. (PMID: 25428182) Int J Mol Sci. 2021 May 06;22(9):. (PMID: 34066354) Curr Opin Pharmacol. 2020 Feb;50:53-60. (PMID: 31877531) Int J Mol Sci. 2023 Dec 19;25(1):. (PMID: 38203185) BMJ. 2014 Dec 19;349:g6258. (PMID: 25527341) JCI Insight. 2023 Dec 8;8(23):. (PMID: 38063197) Front Cell Neurosci. 2015 Sep 01;9:340. (PMID: 26388730) Toxicol Pathol. 2011 Jan;39(1):103-14. (PMID: 21078923) Adv Sci (Weinh). 2023 Feb;10(5):e2202976. (PMID: 36529961) Ageing Res Rev. 2018 Mar;42:72-85. (PMID: 29288112) Nicotine Tob Res. 2020 May 26;22(6):919-924. (PMID: 31403667) Neuron. 2021 Nov 3;109(21):3456-3472.e8. (PMID: 34506725) Ann Med Surg (Lond). 2023 Aug 08;85(10):4887-4902. (PMID: 37811009) Int J Biochem Cell Biol. 2023 Apr;157:106387. (PMID: 36754161) Front Cell Dev Biol. 2021 Feb 25;9:637319. (PMID: 33718373) Front Cell Neurosci. 2021 Jun 29;15:701673. (PMID: 34267628) Cell. 2019 May 30;177(6):1522-1535.e14. (PMID: 31130380) Int J Mol Sci. 2023 Feb 20;24(4):. (PMID: 36835612) ACS Chem Neurosci. 2023 Feb 15;14(4):628-644. (PMID: 36705334) Exp Neurol. 2007 Jun;205(2):414-24. (PMID: 17425956) Brain Pathol. 2023 Jan;33(1):e13108. (PMID: 35816404) Nat Neurosci. 2021 Mar;24(3):312-325. (PMID: 33589835) Prog Mol Biol Transl Sci. 2019;167:1-24. (PMID: 31601399) Microorganisms. 2022 Sep 14;10(9):. (PMID: 36144440) Signal Transduct Target Ther. 2024 Jan 12;9(1):17. (PMID: 38212307) Curr Neuropharmacol. 2018;16(4):415-425. (PMID: 28820052) Cells. 2023 Aug 11;12(16):. (PMID: 37626860) Acta Neuropathol. 2016 Jul;132(1):23-42. (PMID: 27026411) Nicotine Tob Res. 2019 Feb 18;21(3):357-369. (PMID: 30137517) Cell Rep. 2023 Jul 25;42(7):112674. (PMID: 37352098) Mol Brain. 2023 Sep 14;16(1):65. (PMID: 37710343) Int J Mol Sci. 2023 Jan 27;24(3):. (PMID: 36768798) Molecules. 2022 Apr 27;27(9):. (PMID: 35566132) Mol Aspects Med. 2022 Apr;84:101044. (PMID: 34656371) J Neuroinflammation. 2017 Sep 26;14(1):192. (PMID: 28950908) Front Pharmacol. 2023 Feb 02;14:1088957. (PMID: 36817162) J Alzheimers Dis. 2019;67(4):1109-1122. (PMID: 30741675) Front Cell Neurosci. 2019 Nov 12;13:507. (PMID: 31780901) Acta Pharmacol Sin. 2020 Apr;41(4):453-463. (PMID: 32132659) J Neurosci. 2018 Jan 3;38(1):14-25. (PMID: 29298905) Biochemistry (Mosc). 2023 Nov;88(11):1890-1904. (PMID: 38105206) Pharmacol Ther. 2017 Nov;179:1-16. (PMID: 28529069) J Neuroinflammation. 2020 Dec 3;17(1):369. (PMID: 33272299) J Comp Neurol. 2016 Dec 15;524(18):3865-3895. (PMID: 27187682) J Neuroinflammation. 2022 Apr 12;19(1):94. (PMID: 35413868) Neurosci Biobehav Rev. 2020 Aug;115:48-63. (PMID: 32454051) Cold Spring Harb Protoc. 2012 May 01;2012(5):. (PMID: 22550299) Front Mol Neurosci. 2020 Nov 12;13:557647. (PMID: 33328880) J Neuroinflammation. 2012 Oct 30;9:247. (PMID: 23111107) Cold Spring Harb Perspect Med. 2012 Dec 01;2(12):a009621. (PMID: 23071379) Prog Neuropsychopharmacol Biol Psychiatry. 2001 Oct;25(7):1445-57. (PMID: 11513358) Glia. 2010 Nov 1;58(14):1686-700. (PMID: 20629191) Biochim Biophys Acta Mol Basis Dis. 2024 Jan;1870(1):166875. (PMID: 37673358) Annu Rev Pharmacol Toxicol. 2014;54:141-64. (PMID: 24050700) Front Neurosci. 2023 May 15;17:1179611. (PMID: 37255751) Psychopharmacology (Berl). 2021 Sep;238(9):2471-2483. (PMID: 34002247) Allergy Asthma Clin Immunol. 2023 Jun 1;19(1):49. (PMID: 37264452) Acta Neuropathol Commun. 2016 Jul 11;4(1):68. (PMID: 27400748) Mol Neurodegener. 2023 Nov 11;18(1):83. (PMID: 37951933) Trends Neurosci. 2020 Aug;43(8):550-564. (PMID: 32591156) J Neurochem. 2020 Dec;155(5):494-507. (PMID: 31778582) Neurobiol Dis. 2019 Sep;129:1-12. (PMID: 31051233) PLoS Biol. 2017 Aug 22;15(8):e2001993. (PMID: 28829781) Int J Environ Res Public Health. 2021 Jan 29;18(3):. (PMID: 33572734) Glia. 2021 Aug;69(8):2037-2053. (PMID: 33851731) Neurotox Res. 2015 Apr;27(3):217-28. (PMID: 25403520) Trends Neurosci. 2009 Aug;32(8):421-31. (PMID: 19615761) J Neurosci Res. 2023 Dec;101(12):1795-1802. (PMID: 37615647) Mol Psychiatry. 2023 Feb;28(2):518-520. (PMID: 36280754) Pharmacol Res. 2023 Jun;192:106790. (PMID: 37164280) Pharmacol Rev. 2022 Jan;74(1):271-310. (PMID: 35017179) Cell Physiol Biochem. 2022 Feb 9;56(S2):12-30. (PMID: 35133721) Brain Behav Immun. 2021 Jan;91:740-755. (PMID: 33039660) Prog Mol Biol Transl Sci. 2019;167:159-178. (PMID: 31601403) Signal Transduct Target Ther. 2023 Sep 22;8(1):359. (PMID: 37735487) Trends Immunol. 2020 Sep;41(9):805-819. (PMID: 32800705) Biochem Pharmacol. 2023 Jun;212:115532. (PMID: 37019187) Glia. 2015 Aug;63(8):1429-51. (PMID: 26010717) Front Aging. 2023 Sep 06;4:1231706. (PMID: 37744008) Acta Neuropathol. 2007 Sep;114(3):231-41. (PMID: 17576580) Antioxidants (Basel). 2022 Jan 31;11(2):. (PMID: 35204179) Neurol Sci. 2020 Dec;41(12):3609-3615. (PMID: 32458252) Neuron. 2017 Nov 1;96(3):697-708. (PMID: 29096081) Biochem Pharmacol. 2015 Oct 15;97(4):399-407. (PMID: 26093062) BMC Med. 2019 Nov 15;17(1):204. (PMID: 31727112) Int J Mol Sci. 2023 Dec 05;24(24):. (PMID: 38138976) FEBS J. 2020 Sep;287(17):3656-3663. (PMID: 32790936) Ann Neurol. 2016 Nov;80(5):644-659. (PMID: 27649270) Aliment Pharmacol Ther. 2012 Dec;36(11-12):997-1008. (PMID: 23072629) Molecules. 2023 Jan 28;28(3):. (PMID: 36770942) Front Bioeng Biotechnol. 2023 Dec 07;11:1308761. (PMID: 38162183) |
| معلومات مُعتمدة: | R03 AA022479 United States AA NIAAA NIH HHS; S06 GM008016 United States GM NIGMS NIH HHS |
| فهرسة مساهمة: | Keywords: NG2 cells; Parkinson’s disease; acetylcholine; alpha-synuclein; astroglia; dopamine; microglia; neuroinflammation; neuroprotection; nicotine; nicotinic receptors; oligodendrocyte; toll-like receptors |
| المشرفين على المادة: | 0 (Receptors, Nicotinic) 6M3C89ZY6R (Nicotine) VTD58H1Z2X (Dopamine) |
| تواريخ الأحداث: | Date Created: 20240327 Date Completed: 20240328 Latest Revision: 20240330 |
| رمز التحديث: | 20240330 |
| مُعرف محوري في PubMed: | PMC10969434 |
| DOI: | 10.3390/cells13060474 |
| PMID: | 38534318 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2073-4409 |
|---|---|
| DOI: | 10.3390/cells13060474 |